Transform patients’ lives with best in class medicines
Our programs
A portfolio of 6 programs in immunology & oncology
Designing best-in-class medicines with optimal pathways/target coverage, high selectivity & minimal resistance
Best-in-class Salt inducible kinase (SIK) inhibitor entering clinical development for immunology indications in Q3 2025
A unique precision oncology portfolio with several clinical milestones expected starting in 2027
Our philosophy
Right team
Seasoned Drug Discovery and Development Team
Combine deep understanding of disease biology with >150 years of R&D experience and use of state-of-the-art technologies to de-risk early and accelerate value creation.
Right strategy
Patient Centric Strategy with focus on Clinically Validated Targets
Learn from the clinical liabilities of 1st generation drugs to design best-in-class medicines. Develop translational and mechanistic understanding to address liabilities and optimize drugs.
Right drugs
Best Therapeutic Modality For a Clinically Validated Target
Leverage both small and large molecule expertise to tailor drugs to the target biology. Design highly potent and selective drugs to limit off-target effects and optimize safety and efficacy.
Meet the Team
-
Pierre Raboisson
Chief Executive Officer
-
Marie De Vulder
Chief Legal Officer
-
Francois Gonzalvez
Chief Scientific Officer
-
Pieter Peeters
Chief Technology & Operations Officer
-
Sandrine Vendeville
VP, Head of Chemistry
-
Joost Kolkman
VP, Head of Biologics